Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Boehringer Ingelheim, Gilead ink HIV license agreement
November 2011
SHARING OPTIONS:

FOSTER CITY, Calif.Gilead Sciences Inc. and Boehringer Ingelheim announced the formation of a licensing agreement in early October, under which Gilead gained exclusive worldwide rights for the research, development and commercialization of Boehringer Ingelheim's novel non-catalytic site integrase inhibitors (NCINIs) for HIV. The agreement includes the lead compound BI 224436, which has undergone evaluation in a Phase Ia dose- escalation study in healthy volunteers to determine its bioavailability and pharmacokinetics. Boehringer Ingelheim will receive an upfront payment from Gilead, and could receive additional payments based on the achievement of development, regulatory and commercial milestones, in addition to royalties on future sales. Additional financial details were not disclosed. "Both companies' genuine interest in advancing research and development in virology is reflected by this collaboration's aim to address unmet patient needs," said Dr. Norbert Bischofberger, executive vice president of research and development and chief scientific officer of Gilead.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.